[HTML] springer.comFull View

[HTML][HTML] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - Springer
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
被引用次数：78 相关文章
[HTML] nih.gov

[HTML][HTML] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - ncbi.nlm.nih.gov
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[PDF] flinders.edu.au

[PDF][PDF] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - researchnow-admin.flinders.edu.au
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - europepmc.org
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - open.library.ubc.ca
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[PDF] archive.org

[PDF][PDF] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - scholar.archive.org
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[HTML] biomedcentral.com

[HTML][HTML] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner… - Journal of …, 2022 - jneuroinflammation.biomedcentral …
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner… - Journal of …, 2022 - researchnow.flinders.edu.au
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …
[PDF] researchgate.net

[PDF][PDF] Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

E Kamma, W Lasisi, C Libner, HS Ng, JR Plemel - 2022 - researchgate.net
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics.

E Kamma, W Lasisi, C Libner, HS Ng… - Journal of …, 2022 - go.gale.com
There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing-remitting multiple sclerosis (MS), but there are limited treatment …